Brigatinib in Patients With Alectinib‐Refractory ALK‐Positive NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.06.005
Abstract: Introduction: The second‐generation anaplastic lymphoma kinase (ALK) inhibitor alectinib recently showed superior efficacy compared to the first‐generation ALK inhibitor crizotinib in advanced ALK‐rearranged NSCLC, establishing alectinib as the new standard first‐line therapy. Brigatinib, another second‐generation… read more here.
Keywords: positive nsclc; alectinib refractory; alk; alk positive ... See more keywords